novo nordisk glp-1 medications Nordisk's weight-loss pill wins FDA approval Novo Nordisk plans to slash

Semaglutide and cardiovascular outcomes in patients with obesity and prevalent heart failure: a prespecified analysis of the SELECT trial

For most patients, sleep disruption improves meaningfully after the first two to three weeks as the body adjusts

A new ampoule line and ophthalmic gel production are expected to boost capacity and margins in FY26

Wishing you strength and self love on whatever path youre on as long as its kind and respectful to all people

Although there are some experimental skin patches where GLP-1 agonist medicines like semaglutide are used as active ingredients, these are still under trial and not yet approved for use